Recent Company News

• 02:22 PM ET May 22, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 24-May

• 06:04 AM ET May 21, 2026
  

  BeOne Medicines announces presentations at ASCO and EHA 2026 ($308.74, 0.00)

• 05:46 PM ET May 06, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 07:52 AM ET May 20, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:08 AM ET May 20, 2026
  

  CORRECTION: BeOne Medicines did not announces expanded CMS coverage for NeXT Personal minimal residual disease (MRD) test ($297.01, 0.00)

• 06:03 AM ET May 20, 2026
  

  JPMorgan reinstates ALNY, ASND, BMRN, others

• 06:02 AM ET May 20, 2026
  

  BeOne Medicines announces expanded CMS coverage for NeXT Personal minimal residual disease (MRD) test ($297.01, 0.00)

• 01:32 PM ET May 13, 2026
  

  BeOne Medicine receives FDA accelerated approval for BEQALZI for R/R MCL ($317.57, +2.50)

• 09:24 PM ET May 06, 2026
  

  NICE recommends Zymeworks's Ziihera to treat HER2-positive advanced biliary tract cancer after one or more lines of systemic treatment ($27.61, 0.00)